StreetAlpha.app
Home › Stocks › NVAX

Novavax Inc (NVAX)

Healthcare
$7.47
▼ −3.24%
LAST CLOSE · NOV 20

Novavax develops vaccines and licenses its Matrix-M adjuvant to drug makers and governments worldwide. It last closed at $7.47 on Nov 20, down 3.24% on the day. The next earnings report for NVAX is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, NVAX reported EPS of -$0.19 on revenue of $68.3M, with revenue down 3.0% from a year ago. Over its last 8 reports the stock moved an average of 9.3% the session after earnings.

AI Auto Pilots
Is NVAX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NVAX.

Key Stats

Last 12 months
Results
Revenue
$411.6M
−61.3% vs a year ago
Net income
−$76.7M
−122.5% vs a year ago
EPS (diluted)
−$0.52
−125.9% vs a year ago
Gross margin
78.0%
$321.1M gross profit
Valuation
Market cap
$1.2B
165.0M shares
P/E
–
No P/E while losing money
Price to sales
3.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$222.5M
At Sep 30
Debt
$292.1M
At Sep 30
Shareholder equity
−$216.9M
Shares outstanding
165.0M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $2.0B$2.0BFY2022FY2023: $983.7M$983.7MFY2023FY2024: $682.2M$682.2MFY2024FY2025: $1.1B$1.1BFY2025

From NVAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
-$1.25
Same quarter last year
Revenue
$68.3M
−3.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.52Dec '24Mar 2025: $2.93Mar '25Jun 2025: $0.62Jun '25Sep 2025: -$1.25Sep '25Dec 2025: $0.05Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.32Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Dec 2024: $88.3MDec '24Mar 2025: $666.7MMar '25Jun 2025: $239.2MJun '25Sep 2025: $70.4MSep '25Dec 2025: $147.1MDec '25Mar 2026: $139.5MMar '26Jun 2026: $56.7MJun '26Sep 2026: $68.3MSep '26Latest $68.3M
How NVAX moved after its last 8 reports
Average move the session after a report ±9.3%
Nov 5, 2026Time not announced−8.2%
Aug 6, 2026Time not announced+0.5%
May 6, 2026Time not announced+15.6%
Feb 26, 2026Time not announced+17.4%
Jan 12, 2026Time not announced+6.6%
Nov 6, 2025Time not announced−1.3%
Aug 6, 2025Time not announced+12.6%
May 8, 2025Time not announced+11.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NVAXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NVAX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NVAX

Technical Analysis

NVAX · as of the Nov 20 close · updated each morning
Turning down, nearing oversold

The stock is 26% below its 20 day and 38% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $7.27, and the nearest resistance the Pivot at $7.63.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$13.3852 week high+79.1%
$10.3450 day average+38.4%
$9.48100 day average+26.9%
$9.4120 day average+26.0%
$9.32200 day average+24.8%
$8.09Swing high (Aug 7)+8.3%
$7.82Pivot R1+4.7%
$7.63Pivot+2.1%
$7.47Last close
$7.27Pivot S1−2.7%
$7.15Swing low (Jul 28)−4.3%
$6.2052 week low−17.0%
Indicators
RSI (14)32.00Weak, oversold below 30Neutral
MACD-0.77Below its signal lineBearish
Stochastic2.5Near the bottom of its rangeOversold
ADX (14)28.3Trending down
Williams %R-98.9Oversold below −80, overbought above −20Oversold
CCI (20)-137.2Oversold below −100, overbought above 100Oversold
Rate of change−30.7%Change over 10 sessionsBearish
ATR (14)$0.74Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NVAX

What happened before

See how NVAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NVAX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NVAX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NVAXHow many large options trades hit NVAX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NVAX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼104 buying vs 125 selling
  • ▲Held by funds +1.6 pts
  • ▼Funds holding -9
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 2.92 to 4.34
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding262271−3.3%
In funds' top 1032+50.0%
Held by funds72.8%71.2%+1.6 pts
New / increased30 / 7440 / 75−9.6%
Reduced / sold out85 / 4089 / 32+3.3%
Put/call ratio4.342.92+48.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NVAX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NVAX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 31, 2024James F YoungDirectorSale10,000$8.22$82K
Dec 13, 2024Rachel K. KingDirectorSale4,150$9.02$37K
Every insider buy and sale for NVAX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NVAX insider trades →

From SEC Form 4 filings by NVAX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVAX is in one of them and how their past NVAX trades turned out.

NVAX in the AI portfolios
Loading…

NVAX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NVAX in an article yet. Here's the latest on the wider market.

NVAX in the news

NVAX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 5
Who traded NVAX · since 2020
Latest 2 filings
$1K – $15KTraded Oct 13, 2020Filed Nov 5, 2020
$1K – $15KTraded Aug 17, 2020Filed Aug 30, 2020
PersonTypeAmountTradedFiledDelay
Charles RobertsR · KSSell$1K – $15KOct 13, 2020Nov 5, 202023 d
Charles RobertsR · KSBuy$1K – $15KAug 17, 2020Aug 30, 202013 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Novavax

Novavax is a vaccine company based in Gaithersburg, Maryland. It develops vaccines using a platform built on protein nanoparticles, and its COVID-19 vaccine, Nuvaxovid, is sold with Sanofi leading commercialization. The company also licenses its Matrix-M adjuvant, which helps vaccines produce a stronger immune response, to partners such as the Serum Institute of India and other drug makers. Its customers include national governments and global pharmaceutical companies.

Headquarters
Gaithersburg, MD
Founded
1987